Getz Pharma (Pvt) Limited
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private branded-generic pharmaceutical manufacturer · Karachi · Pakistan
International branded-generic pharmaceutical manufacturer headquartered in Karachi with operations across multiple therapeutic areas and countries.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Getz Pharma (Pvt.) Limited
- Company type
- Private branded-generic pharmaceutical manufacturer
- Address
- 29-30/27, Korangi Industrial Area, Karachi, Sindh, Pakistan
- Website
- getzpharma.com ↗
- Phone
- +92 21 111 111 511
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Getz Pharma (Pvt) Limited is priced against the market
254 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Diampa-M + | Empagliflozin + Metformin | 5 mg + 850 mg | Tablet | 14's | 103093 | PKR 766.21 | PKR 54.73/tablet | 🔒 Pharma Pro |
| Diampa-M + | Empagliflozin + Metformin | 5 mg + 850 mg | Tablet | 10's | 103093 | PKR 546.18 | PKR 54.62/tablet | 🔒 Pharma Pro |
| Diampa-M + | Empagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 14's | 103094 | PKR 768.13 | PKR 54.87/tablet | 🔒 Pharma Pro |
| Diampa-M + | Empagliflozin + Metformin | 5 mg + 500 mg | Tablet | 14's | 105287 | PKR 680.82 | PKR 48.63/tablet | 🔒 Pharma Pro |
| Diampa-M + | Empagliflozin + Metformin | 12.5 mg + 500 mg | Tablet | 14's | 105551 | PKR 658.09 | PKR 47.01/tablet | 🔒 Pharma Pro |
| Diampa-M + | Empagliflozin + Metformin | 12.5 mg + 850 mg | Tablet | 14's | 105552 | PKR 668.03 | PKR 47.72/tablet | 🔒 Pharma Pro |
| Diampa-M XR | Empagliflozin + Metformin | 5 mg + 1000 mg | Extended-release tablet | 28's | 114327 | PKR 1,368.75 | PKR 48.88/tablet | 🔒 Pharma Pro |
| Diampa-M XR | Empagliflozin + Metformin | 10 mg + 1000 mg | Extended-release tablet | 28's | 114328 | PKR 1,616.07 | PKR 57.72/tablet | 🔒 Pharma Pro |
| Diampa-M XR | Empagliflozin + Metformin | 12.5 mg + 1000 mg | Extended-release tablet | 28's | 114329 | PKR 1,618.91 | PKR 57.82/tablet | 🔒 Pharma Pro |
| Diampa-M XR + | Empagliflozin + Metformin | 5 mg + 1000 mg | Extended-release tablet | 14's | 114327 | PKR 697.89 | PKR 49.85/tablet | 🔒 Pharma Pro |
| Diampa-M XR + | Empagliflozin + Metformin | 10 mg + 1000 mg | Extended-release tablet | 14's | 114328 | PKR 824.38 | PKR 58.88/tablet | 🔒 Pharma Pro |
| Diampa-M XR + | Empagliflozin + Metformin | 12.5 mg + 1000 mg | Extended-release tablet | 14's | 114329 | PKR 825.80 | PKR 58.99/tablet | 🔒 Pharma Pro |
| Diampa-M XR + | Empagliflozin + Metformin | 25 mg + 1000 mg | Extended-release tablet | 14's | 114330 | PKR 837.18 | PKR 59.80/tablet | 🔒 Pharma Pro |
| Dravix | Tranexamic acid | 500 mg/5 mL | Injection | 10's | 076447 | PKR 1,755.54 | PKR 175.55/vial/unit | 🔒 Pharma Pro |
| Dravix | Tranexamic acid | 500 mg | Capsule | 20's | 076449 | PKR 492.02 | PKR 24.60/capsule | 🔒 Pharma Pro |
| Fectopime Powder for Injection 1gRegistry verified | Sterile Cefepime Hydrochloride Monohydrate Eq. to Cefepime (with L-Arginine | — | — | — | 118059Official source ↗ | No indexed price | — | — |
| Fectopime Powder for Injection 2gRegistry verified | Sterile Cefepime Hydrochloride Monohydrate Eq. to Cefepime (with L-Arginine | — | — | — | 118058Official source ↗ | No indexed price | — | — |
| Fectopime Powder for Injection 500mgRegistry verified | Sterile Cefepime Hydrochloride Monohydrate Eq. to Cefepime (with L-Arginine | — | — | — | 118060Official source ↗ | No indexed price | — | — |
| Ferotein Chewable + | Iron protein succinylate + Folic acid | 400 mg + 2.5 mg | Tablet | 14's | 050645 | PKR 336.43 | PKR 24.03/tablet | 🔒 Pharma Pro |
| Folic Acid | Folic acid | 5 mg | Tablet | 10 X 10's | 086939 | PKR 61.04 | PKR 0.61/tablet | 🔒 Pharma Pro |
| Formiget | Budesonide + Formoterol | 200 mcg + 6 mcg | Inhalation capsule | 30's | 098723 | PKR 547.07 | PKR 18.24/capsule | 🔒 Pharma Pro |
| Formiget | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 30's | 098828 | PKR 911.78 | PKR 30.39/capsule | 🔒 Pharma Pro |
| Fortide | Budesonide + Formoterol | 200 mcg + 6 mcg per metered dose | Metered-dose inhaler | 1's | 081540 | PKR 1,248.56 | PKR 1,248.56/dose | No comparator |
| Fortide JuniorSource observed | Budesonide + Formoterol | 200 mcg + 6 mcg per metered dose; delivered dose 160 mcg + 4.5 mcg | Metered-dose inhaler | 1's | 118331Official source ↗ | No indexed price | — | — |
| Fortide Junior Inhaler +Source observed | Budesonide + Formoterol | 100 mcg + 6 mcg | — | 1's | 118331Official source ↗ | No indexed price | — | — |
| Getacet | Acetazolamide | 250 mg | Tablet | 3 x 10's | 098716 | PKR 76.98 | PKR 2.57/tablet | 🔒 Pharma Pro |
| Getamlo | Amlodipine | 5 mg | Tablet | 20's | 114473 | PKR 216.86 | PKR 10.84/tablet | 🔒 Pharma Pro |
| Getamlo | Amlodipine | 10 mg | Tablet | 20's | 114474 | PKR 299.47 | PKR 14.97/tablet | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 500 mg | IV injection | 1's | 019875 | PKR 433.37 | PKR 433.37/vial/unit | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 1 g | IV injection | 1's | 019876 | PKR 852.66 | PKR 852.66/vial/unit | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 1000 mg | IV injection | 1's | 019876 | PKR 852.66 | PKR 852.66/vial/unit | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 500 mg | IM injection | 1's | 024627 | PKR 423.40 | PKR 423.40/vial/unit | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 250 mg | IM injection | 1's | 024628 | PKR 247.84 | PKR 247.84/vial/unit | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 250 mg | IV injection | 1's | 024629 | PKR 247.84 | PKR 247.84/vial/unit | 🔒 Pharma Pro |
| Getofin | Ceftriaxone | 2000 mg | IV injection | 1's | 118052 | PKR 929.41 | PKR 929.41/vial/unit | 🔒 Pharma Pro |
| Getzid MR | Gliclazide | 30 mg | Tablet | 30's | 102854 | PKR 397.99 | PKR 13.27/tablet | 🔒 Pharma Pro |
| Getzid MR | Gliclazide | 60 mg | Tablet | 30's | 102855 | PKR 660.10 | PKR 22.00/tablet | 🔒 Pharma Pro |
| Getzpenem | Meropenem | 500 mg | Powder for injection | 1's | 083174 | PKR 2,071.05 | PKR 2,071.05/vial/unit | 🔒 Pharma Pro |
| Getzpenem | Meropenem | 1 g | Powder for injection | 1's | 083175 | PKR 3,925.94 | PKR 3,925.94/vial/unit | 🔒 Pharma Pro |
| HCQ | Hydroxychloroquine | 200 mg | Tablet | 30's | 045471 | PKR 583.79 | PKR 19.46/tablet | 🔒 Pharma Pro |
| Insuget 70/30Source observed | Human insulin premix 30/70 (30% regular + 70% NPH) | 100 IU/mL | Injection | 1's | 050649Official source ↗ | No indexed price | — | — |
| Insuget 70/30Source observed | Human insulin (isophane/NPH) | 100 IU | Injection | 1's | 050649Official source ↗ | No indexed price | — | — |
| Insuget N | Human insulin (isophane/NPH) | 100 IU/mL | Suspension for injection | 1's | 050648 | PKR 1,094.64 | PKR 1,094.64/vial/unit | 🔒 Pharma Pro |
| Insuget R | Regular human insulin | 100 IU/mL | Injection | 1's | 050647 | PKR 1,094.64 | PKR 1,094.64/vial/unit | No comparator |
| Insuget R | Human insulin (isophane/NPH) | 100 IU | Injection | 1's | 050647 | PKR 1,094.64 | PKR 1,094.64/vial/unit | No comparator |
| Insulog | Insulin lispro | 100 units/mL | Injection | 3ml x 5's | 099075 | PKR 3,331.88 | PKR 222.13/mL | No comparator |
| Insulog | Insulin lispro | 100 units/mL | Injection | 3ml x 1's | 099075 | PKR 666.37 | PKR 222.12/mL | No comparator |
| Insulog | Insulin lispro | 100 units/mL | Injection | 3ml x 3's | 099075 | PKR 1,994.31 | PKR 221.59/mL | No comparator |
| Leflox | Levofloxacin | 500 mg/100 mL | IV infusion | 1 x 100 ml | 024664 | PKR 1,377.68 | PKR 13.78/mL | 🔒 Pharma Pro |
| Leflox | Levofloxacin | 500 mg | Tablet | 5 x 10's | 026163 | PKR 3,212.01 | PKR 64.24/tablet | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.